ImpediMed Ltd
ASX:IPD

Watchlist Manager
ImpediMed Ltd Logo
ImpediMed Ltd
ASX:IPD
Watchlist
Price: 0.051 AUD -1.92% Market Closed
Market Cap: 103.2m AUD
Have any thoughts about
ImpediMed Ltd?
Write Note

ImpediMed Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ImpediMed Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
ImpediMed Ltd
ASX:IPD
Cash Equivalents
AU$18.4m
CAGR 3-Years
17%
CAGR 5-Years
18%
CAGR 10-Years
N/A
R
Respiri Ltd
ASX:RSH
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cyclopharm Ltd
ASX:CYC
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cochlear Ltd
ASX:COH
Cash Equivalents
AU$513.6m
CAGR 3-Years
-6%
CAGR 5-Years
46%
CAGR 10-Years
25%
Optiscan Imaging Ltd
ASX:OIL
Cash Equivalents
AU$6.1m
CAGR 3-Years
-10%
CAGR 5-Years
28%
CAGR 10-Years
56%
EMvision Medical Devices Ltd
ASX:EMV
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ImpediMed Ltd
Glance View

Market Cap
103.2m AUD
Industry
Health Care

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.

IPD Intrinsic Value
0.08 AUD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is ImpediMed Ltd's Cash Equivalents?
Cash Equivalents
18.4m AUD

Based on the financial report for Jun 30, 2024, ImpediMed Ltd's Cash Equivalents amounts to 18.4m AUD.

What is ImpediMed Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
18%

Over the last year, the Cash Equivalents growth was 36%. The average annual Cash Equivalents growth rates for ImpediMed Ltd have been 17% over the past three years , 18% over the past five years .

Back to Top